Stocks have fallen this year due to Donald Trump’s trade policy. The 47th US President decided to impose sudden tariffs on imports from most countries, but he significantly rewind these plans, but at least paused.
Of all volatility, some companies have proven resilient by performing far better than the market. Some of these seem like great buying and holding options, especially for income-seeking investors. Consider two such companies. amgen (NASDAQ: AMGN) and Novartis (NYSE: NVS).
Where would you invest $1,000 now? Our team of analysts revealed what they believe 10 Best Stocks Buy now. Continues “
President Trump doesn’t spare Pharmaceutical Industry For now, tariffs indicate that his administration could change soon. In other words, drugmakers like Amgen may see a meaningful effect on their revenue. According to some industry CEOs, tariffs are Less innovation in this area. Still, life-saving drug development is a business that never loses its style, regardless of the economic situation.
An adaptable drug maker can work well in the long run. Amgen is one of them. Biotechnology has a long list of approved drugs in multiple therapeutic areas. Last year, 13 products generated at least $1 billion in annual sales. Most of these saw their sales move in the right direction.
Amgen boasts several exciting growth drivers. Tepezza continues to be the only therapy approved by the US Food and Drug Administration (FDA) for thyroid eye disease. Biotechnology aims to regulate the drug in other countries.
Amgen treatment for asthma, Tezspire, joint market AstraZenecaThe performance has also been on good progress, continuing to record important clinical victories leading to label expansion. Bone disease in postmenopausal women Old drugs such as high cholesterol and reposa for homogeneity used to treat osteoporosis are still one of Amgen’s best performances.
Finally, the company has a deep pipeline. Despite Phase 2 data from weight management candidate Maritide, it failed to impress, but the research drug could open a solid niche in the fast-growing weight loss market. Amgen has many other exciting programs in its pipeline.
Of all the economic issues we have experienced over the past five years, biotechnology continues to increase its dividends. Amgen’s payments have increased by 201% over the past decade, offering a forward yield of 3.2% at Wednesday’s price.
Amgen’s strong defensive presence, excellent innovative track record and a strong dividend program will help you retain your top stock.
Novartis already plans to avoid tariffs imposed on the pharmaceutical industry. The drugmaker recently announced a five-year, $23 billion manufacturing project in the US, which could help in the long term, but highlights key points, particularly for highly successful companies. Novartis owes it to its solid foundational operation. That topline growth rarely blows away investors, but it records steady revenue and profits.
In today’s unstable environment, a slow and stable thing may be what your doctor ordered. Certainly, Novartis will face several patent cliffs this year. This is less important than the company’s top selling drug, Antresto, the heart failure drug. Novartis’ revenues can drop once it occurs. This is because it is usually done for drug manufacturers who lose patent exclusivity for bestselling products.
However, Novartis should be able to overcome that. The company has several new growth drivers that will become more prominent. Fabharta, a treatment for rare blood disorders, won the green light in 2023, but Van Raffia, a kidney disease drug, did so only this month. Novartis’ deep pipeline leads to more approvals. The company’s dividend record speaks volumes of its ability to navigate difficult conditions. Novartis has increased its payments for the 28th consecutive year.
The company also offers a dividend yield of 3.5%. Whether it’s stability or income, Novartis is forever a great choice for investors.
Consider this before purchasing stock at Amgen.
Motley Fool Stock Advisor The analyst team has identified what they believe 10 Best Stocks For investors to buy now…and Amgen was not one of them. The 10 stocks that have made the cut could potentially generate monster returns over the next few years.
When should you think about it? Netflix I created this list on December 17, 2004…If you invested $1,000 at the time of recommendation, There is $518,599! * Or when nvidia I created this list on April 15, 2005… If you invested $1,000 at the time of recommendation, There is $640,429! *
Now it’s worth noting Stock AdvisorThe average return rate 794% – Market-breaking outperformance compared to 153% For the S&P 500. Don’t miss out on the latest Top 10 list that you can use when participating Stock Advisor.
View 10 shares »
*Stock Advisor will return as of April 14, 2025
Prosperous Junior Bty There is no position in any of the stocks mentioned. Motley Fool has a position in Amgen and recommends. Motley Fool recommends AstraZeneca plc. To Motley’s fool Disclosure Policy.
Two dividend stocks refuse to revise the market for customs fuel fuel and buy and hold forever Originally published by The Motley Fool
